Call Us
Everhope Logo
Prostate Cancer
Therapy
Hormone Therapy for Prostate Cancer - Advanced Cancer Care

Hormone Therapy for Prostate Cancer - Advanced Cancer Care

Hormone Therapy for Prostate Cancer

Hormone therapy is the cornerstone of treatment for advanced prostate cancer. By targeting testosterone—the hormone that fuels prostate cancer growth—hormone therapy controls cancer, extends survival, and improves quality of life.

Overview of Hormone Therapy for Prostate Cancer

What is Hormone Therapy for Prostate Cancer?

Hormone therapy for prostate cancer, also called androgen deprivation therapy (ADT), reduces testosterone levels or blocks testosterone from reaching cancer cells. Since prostate cancer depends on testosterone to grow, removing this fuel starves cancer cells.

How Does Hormone Therapy for Prostate Cancer Work?

How does hormone therapy for prostate cancer work? Testosterone binds to receptors on prostate cancer cells, signaling them to grow. Hormone therapy interrupts this:

  • •Reducing testosterone production
    LHRH agonists and antagonists stop the testicles from making testosterone, achieving castration levels within weeks.
  • •Blocking testosterone action
    Androgen receptor blockers prevent testosterone from binding to cancer cells. Androgen synthesis inhibitors block cancer cells from making their own testosterone.

Modern hormone therapy for men with prostate cancer often combines these approaches for superior cancer control.

Types of Hormone Therapy Drugs

  • •LHRH Agonists
    (leuprolide/Lupron, goserelin/Zoladex) are injections given monthly, every 3 months, or every 6 months.
  • •LHRH Antagonists
    (degarelix/Firmagon, relugolix/Orgovyx) work faster without testosterone 'flare.' Relugolix is oral; degarelix requires injections.
  • •Antiandrogens
    include first-generation (bicalutamide, flutamide) and second-generation (enzalutamide/Xtandi, apalutamide/Erleada, darolutamide/Nubeqa) which provide stronger receptor blockade.
  • •Androgen Synthesis Inhibitors
    like abiraterone (Zytiga) block enzymes cancer cells use to make testosterone.

When Hormone Therapy is Needed

For Localized High-Risk Prostate Cancer

Hormone therapy combined with radiation significantly improves cure rates for high-risk localized cancer. Adding ADT to radiation reduces recurrence risk by up to 50% and improves 15-year survival.

Treatment typically involves 6 months of ADT for intermediate-risk or 18-36 months for high-risk disease, given with radiation.

For Advanced or Metastatic Disease

Hormone therapy for men with prostate cancer who have metastatic disease is primary treatment. Now, men receive ADT plus abiraterone, enzalutamide, apalutamide, darolutamide, or docetaxel chemotherapy.

This combination approach dramatically improves outcomes. Median survival with ADT alone was 32 months. Modern combinations extend survival to 48-60 months or longer.

For Castration-Resistant Disease

When cancer progresses despite castration-level testosterone, hormone therapy continues while adding newer agents. Second-generation antiandrogens remain effective, extending survival by 4-6 months.

For Biochemical Recurrence

When PSA rises after surgery or radiation, hormone therapy may be delayed or started when PSA reaches certain levels.

Treatment Process

How Long is Hormone Therapy for Prostate Cancer?

  • •With radiation for localized disease
    6 months (intermediate-risk) to 18-36 months (high-risk)
  • •For metastatic hormone-sensitive disease
    Indefinitely, continuing as long as effective
  • •For castration-resistant disease
    Continuously, switching between drugs as cancer progresses

Intermittent Hormone Therapy for Prostate Cancer

Intermittent hormone therapy for prostate cancer involves treatment 'holidays' where therapy stops when PSA drops low, then restarts when PSA rises. This may reduce side effects while maintaining effectiveness for select non-metastatic patients.

WhatsApp Cancer Care
Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp
India's First Cancer Care Management Platform
Free to start•Secure & private•No app download needed

Studies show intermittent therapy works as well as continuous therapy for some men, though it's not suitable for metastatic disease.

Administration Methods

LHRH agonists and antagonists are injections given monthly, every 3 months, or every 6 months.

Oral medications include relugolix (daily), abiraterone (4 pills daily with prednisone), enzalutamide (4 capsules daily), apalutamide (4 tablets daily), and darolutamide (2 tablets twice daily).

Regular monitoring includes PSA tests every 3-6 months, testosterone level checks, bone density scans, and cardiovascular monitoring.

Benefits and Risks

Benefits of Hormone Therapy for Prostate Cancer

Highly effective: Over 90% of men respond initially, with PSA dropping dramatically within weeks.

Extended survival: Adding abiraterone to ADT for high-risk non-metastatic disease reduces death risk by 40%. For metastatic disease, modern combinations extend median survival from 32 months to 48-60+ months.

Enables curative radiation: Combined with radiation for high-risk localized disease, hormone therapy significantly improves cure rates.

Hormone Therapy for Prostate Cancer Survival Rates

  • •For high-risk non-metastatic disease
    (ADT plus abiraterone): 6-year metastasis-free survival 82% (vs 69% ADT alone), 6-year overall survival 86% (vs 77% ADT alone).
  • •For metastatic hormone-sensitive disease
    median overall survival 48-60+ months with modern combinations.

Side Effects of Hormone Therapy for Prostate Cancer

Side Effects of hormone therapy for prostate cancer result from testosterone suppression:

  • •Sexual side effects
    Decreased libido, erectile dysfunction affecting most men.
  • •Hot flashes
    Occur in 50-80% of men, often improving over time.
  • •Fatigue
    Common, requiring lifestyle adjustments and exercise.
  • •Muscle loss and weight gain
    Occur with long-term therapy. Exercise and diet help minimize this.
  • •Bone density loss
    Increases fracture risk. Bone-protecting medications reduce this.
  • •Metabolic changes
    Increased diabetes and cardiovascular disease risk, requiring monitoring.
  • •Cognitive changes
    Memory issues, difficulty concentrating affect some men.
  • •Mood changes
    Depression and irritability can occur.

Effects of Hormone Therapy for Prostate Cancer

Effects of hormone therapy for prostate cancer include dramatic PSA reductions (often to undetectable levels), tumor shrinkage, symptom improvement, and delayed disease progression.

Aftercare and Recovery

Managing Side Effects

  • •Exercise regularly
    Resistance training maintains muscle and bone. Cardiovascular exercise helps fatigue and weight management.
  • •Nutrition
    High-protein diet supports muscle. Calcium (1000-1200 mg daily) and vitamin D (800-1000 IU daily) protect bones.
  • •Bone health
    Take prescribed bone-protecting medications.
  • •Cardiovascular health
    Monitor blood pressure, cholesterol, blood sugar.
  • •Sexual health
    Discuss erectile dysfunction treatments with your doctor.
  • •Mental health
    Address mood changes through counseling, support groups, or medications.
  • •Regular monitoring
    Attend all appointments for PSA checks and side effect assessment.

Hormone Therapy for Prostate Cancer Life Expectancy

  • •For high-risk non-metastatic disease
    modern hormone therapy combined with radiation achieves potential cure, with many men living normal life spans.
  • •For metastatic hormone-sensitive disease
    modern combinations achieve median survival of 48-60+ months, with 6-year survival rates around 50-60%.
  • •For castration-resistant disease
    sequential hormone therapies can control disease for additional years.

Why Choose Everhope

Everhope's hormone therapy program provides comprehensive, personalized care. Our approach includes precision selection of optimal hormone therapy based on cancer characteristics, genomic profiling to identify which patients benefit from specific treatments, comprehensive side effect management including bone protection and cardiovascular monitoring, and integration with other treatments.

Our multidisciplinary team optimizes treatment sequences, ensuring you receive the right therapy at the right time. Support services including exercise physiology, nutrition counseling, and psychological support help maintain quality of life throughout therapy.

FAQs

Initial response typically lasts 18-36 months for metastatic disease with ADT alone. Modern combinations (ADT plus abiraterone/enzalutamide) extend control to 48-60+ months. When cancer becomes castration-resistant, sequential hormone therapies can provide years of additional control.

Many men maintain good quality of life on hormone therapy, though adjustments are needed. Regular exercise, healthy diet, and side effect management help. Sexual function changes affect most men. Work, hobbies, and daily activities usually continue with adaptations for fatigue.

Sexual side effects (erectile dysfunction, decreased libido) affect most men and can be emotionally challenging. Bone density loss increases fracture risk, requiring bone-protecting medications. Cardiovascular changes increase heart disease and diabetes risk, requiring monitoring. Fatigue, muscle loss, and mood changes significantly impact some men's quality of life.

Hormone therapy alone rarely cures cancer, but combined with radiation for localized high-risk disease, it significantly improves cure rates. For metastatic disease, hormone therapy controls cancer (sometimes for many years) but doesn't eliminate it. Men typically remain on treatment long-term.

Intermittent therapy (treatment breaks when PSA drops low) may reduce side effects for select non-metastatic patients while maintaining effectiveness. Continuous therapy is standard for metastatic disease. Discuss your specific situation with your oncologist to determine the best approach.

When cancer progresses (castration-resistant disease), you continue ADT while adding second-generation hormone drugs (enzalutamide, abiraterone, apalutamide), chemotherapy, or newer targeted treatments. Sequential therapies can control disease for years after initial hormone therapy resistance.

For metastatic disease, adding abiraterone or enzalutamide to ADT extends median survival from 32 months (ADT alone) to 48-60+ months. For high-risk non-metastatic disease, adding abiraterone reduces death risk by 40% and metastasis risk by 47% compared to ADT alone.